| Title |
Neurologic uses of botulinum neurotoxin type A
|
|---|---|
| Published in |
Neuropsychiatric Disease and Treatment, January 2008
|
| DOI | 10.2147/ndt.s1612 |
| Pubmed ID | |
| Authors |
John P Ney, Kevin R Joseph |
| Abstract |
This article reviews the current and most neurologic uses of botulinum neurotoxin type A (BoNT-A), beginning with relevant historical data, neurochemical mechanism at the neuromuscular junction. Current commercial preparations of BoNT-A are reviewed, as are immunologic issues relating to secondary failure of BoNT-A therapy. Clinical uses are summarized with an emphasis on controlled clinical trials (as appropriate), including facial movement disorders, focal neck and limb dystonias, spasticity, hypersecretory syndromes, and pain. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 78 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 1% |
| United States | 1 | 1% |
| Brazil | 1 | 1% |
| Unknown | 75 | 96% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 16 | 21% |
| Student > Bachelor | 13 | 17% |
| Researcher | 6 | 8% |
| Other | 6 | 8% |
| Student > Doctoral Student | 6 | 8% |
| Other | 12 | 15% |
| Unknown | 19 | 24% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 26 | 33% |
| Nursing and Health Professions | 9 | 12% |
| Agricultural and Biological Sciences | 7 | 9% |
| Psychology | 4 | 5% |
| Neuroscience | 3 | 4% |
| Other | 8 | 10% |
| Unknown | 21 | 27% |
Attention Score in Context
This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 10 August 2021.
All research outputs
#4,835,465
of 25,371,288 outputs
Outputs from Neuropsychiatric Disease and Treatment
#684
of 3,132 outputs
Outputs of similar age
#21,140
of 168,384 outputs
Outputs of similar age from Neuropsychiatric Disease and Treatment
#5
of 18 outputs
Altmetric has tracked 25,371,288 research outputs across all sources so far. Compared to these this one has done well and is in the 79th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,132 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.6. This one has done well, scoring higher than 76% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 168,384 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 86% of its contemporaries.
We're also able to compare this research output to 18 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 66% of its contemporaries.